Biotechnology Analysis & Statistics, July 2014 (p30)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

871-900 of about 2 400 reports

Purchase Reports From Reputable Market Research Publishers

Mabion SA (MAB) - Financial and Strategic SWOT Analysis Review

Mabion SA (MAB) - Financial and Strategic SWOT Analysis Review

  • $ 125
  • Company report
  • July 2014
  • by Global Data

Mabion SA (MAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to ...

  • Industries : Biopharmaceutical
  • Countries : Iceland
Sports Nutrition Market Overview in Brazil

Sports Nutrition Market Overview in Brazil

  • $ 898
  • Industry report
  • July 2014
  • by Euromonitor International

Creatine was released by ANVISA (Health Surveillance Agency) to be sold as sport nutrition in May 2010. Prior to that, creatine was classified a medicine by ANVISA and sports nutrition manufacturers had ...

  • Industries : Sport Nutritional, Biopharmaceutical
  • Countries : Brazil
Sports Nutrition Market Analysis in New Zealand

Sports Nutrition Market Analysis in New Zealand

  • $ 898
  • Industry report
  • July 2014
  • by Euromonitor International

This is evident in 2010’s growth of 1%, being lower than the review period CAGR of 4%. Euromonitor International's report offers a comprehensive guide to the size and shape of the industry at a national ...

  • Industries : Sport Nutritional, Biopharmaceutical
  • Countries : New Zealand
Advances in Enzyme Technology for the Food Industry

Advances in Enzyme Technology for the Food Industry

  • $ 240
  • Industry report
  • July 2014
  • by Food Tech. Intelligence

Food Technology Intelligence, Inc. offers a revised and updated in-depth report analyzing several new developments in enzyme research. The report will give you a first-hand look at many commercially-viable ...

  • Industries : Biopharmaceutical, Agriculture
Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders - Overview

Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders - Overview

  • $ 2 495
  • Industry report
  • July 2014
  • by CHI Insight Pharma Reports

Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders has a focus in biomarkers for neurodegenerative diseases and diagnostic applications in development. Biomarkers ...

  • Industries : Genomics
  • Countries : United States
Biomarkers in Alzheimers Disease

Biomarkers in Alzheimers Disease

  • $ 699
  • Industry report
  • July 2014
  • by CHI Insight Pharma Reports

Overview Biomarkers in Alzheimer's Disease is focused on the biomarker identification and development in patients with Alzheimer's Disease. As a spin-off of Biomarkers: Discovery and Development for a ...

  • Industries : Genomics
Glucagon-Like Peptide 2 (GLP-2) Agonists -Pipeline Insights, 2014

Glucagon-Like Peptide 2 (GLP-2) Agonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
GM-CSF Inhibitors -Pipeline Insights, 2014

GM-CSF Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biological Therapy
Heat Shock Protein 27 (Hsp27) Inhibitors -Pipeline Insights, 2014

Heat Shock Protein 27 (Hsp27) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
Heat Shock Protein 70 (Hsp70) Inhibitors -Pipeline Insights, 2014

Heat Shock Protein 70 (Hsp70) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2014

Insulin Like Growth Factor 2 (IGF-2) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
Protein Kinase C Beta (PKC-Beta) Inhibitors -Pipeline Insights, 2014

Protein Kinase C Beta (PKC-Beta) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors -Pipeline Insights, 2014

Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
Tumor Necrosis Factor Alpha (TNF-a) Agonists -Pipeline Insights, 2014

Tumor Necrosis Factor Alpha (TNF-a) Agonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

  • Industries : Biopharmaceutical
5-Lipoxygenase Activating Protein (FLAP) Inhibitors -Pipeline Insights, 2014

5-Lipoxygenase Activating Protein (FLAP) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“5-Lipoxygenase Activating Protein (FLAP) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2) -Pipeline Insights, 2014

Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2) -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Alpha2beta1 Integrin Antagonists (Very Late Antigen 2 (VLA-2)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of ...

  • Industries : Biopharmaceutical
AMP Activated Protein Kinase (AMPK) Inhibitors -Pipeline Insights, 2014

AMP Activated Protein Kinase (AMPK) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“AMP Activated Protein Kinase (AMPK) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A ...

  • Industries : Biopharmaceutical
Amyloid Protein Blockers -Pipeline Insights, 2014

Amyloid Protein Blockers -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Amyloid Protein Blockers-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Anti GM-CSF Antibody -Pipeline Insights, 2014

Anti GM-CSF Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti GM-CSF Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biological Therapy
Anti-CD105 Antibody -Pipeline Insights, 2014

Anti-CD105 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD105 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD152 Antibody -Pipeline Insights, 2014

Anti-CD152 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD152 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD19 Antibody -Pipeline Insights, 2014

Anti-CD19 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD19 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD22 Antibody -Pipeline Insights, 2014

Anti-CD22 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD22 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD25 Antibody -Pipeline Insights, 2014

Anti-CD25 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD25 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014

Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD274 (PD-L1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014

Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Anti-CD28 Antibody -Pipeline Insights, 2014

Anti-CD28 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD28 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD3 Antibody -Pipeline Insights, 2014

Anti-CD3 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD3 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD30 Antibody -Pipeline Insights, 2014

Anti-CD30 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD30 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD33 Antibody -Pipeline Insights, 2014

Anti-CD33 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD33 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical

About 100 Companies

Read our Company Profiles

Johnson and Johnson

United States

GlaxoSmithKline P.L.C.

United States

Life Technologies Corp.

United States

Abbott Laboratories

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.